{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:12:31Z","timestamp":1775041951804,"version":"3.50.1"},"reference-count":65,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00675","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T03:54:36Z","timestamp":1497239676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Amy K.","family":"Erbe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick K.","family":"Reville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakeesha","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eneida A.","family":"Mendonca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn A.","family":"Hank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy B.","family":"London","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Hogarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Ozkaynak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Sondel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0161-5890(02)00030-5","article-title":"A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors","volume":"38","author":"Boyington","year":"2002","journal-title":"Mol Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.immunol.20.092501.134942","article-title":"KIR: diverse, rapidly evolving receptors of innate and adaptive immunity","volume":"20","author":"Vilches","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrg1489","article-title":"Gene map of the extended human MHC","volume":"5","author":"Horton","year":"2004","journal-title":"Nat Rev Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.180.2.537","article-title":"NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules","volume":"180","author":"Litwin","year":"1994","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.184.2.505","article-title":"The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58\/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer","volume":"184","author":"Pende","year":"1996","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","article-title":"Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy","volume":"70","author":"Delgado","year":"2010","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/2326-6066.CIR-13-0158","article-title":"CALGB 150905 (alliance): rituximab broadens the anti-lymphoma response by activating unlicensed NK cells","volume":"2","author":"Du","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.4049\/jimmunol.180.6.3969","article-title":"Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3","volume":"180","author":"Moesta","year":"2008","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1172\/JCI62749","article-title":"Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment","volume":"122","author":"Tarek","year":"2012","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0065-2776(08)01002-X","article-title":"Natural killer cell tolerance licensing and other mechanisms","volume":"101","author":"Jonsson","year":"2009","journal-title":"Adv Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1600-065X.2006.00458.x","article-title":"Licensing of natural killer cells by self-major histocompatibility complex class I","volume":"214","author":"Yokoyama","year":"2006","journal-title":"Immunol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1126\/science.1853205","article-title":"MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity","volume":"253","author":"Liao","year":"1991","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2010.08.031","article-title":"Natural killer cell education and tolerance","volume":"142","author":"Orr","year":"2010","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1200\/JCO.2015.64.9558","article-title":"KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma","volume":"34","author":"Forlenza","year":"2016","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1158\/1078-0432.CCR-09-1720","article-title":"KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma","volume":"15","author":"Venstrom","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-LB-048","article-title":"Impact of KIR\/KIR ligand genotype for neuroblastoma patients in a phase 3 COG immunotherapy trial","volume-title":"AACR Annual Meeting (Abstract)","author":"Erbe","year":"2017"},{"key":"B21","article-title":"KIR\/KIR-ligand genotypes influence clinical response to dinutuximab-based immunotherapy in high-risk neuroblastoma patients","author":"Reville","year":"2017"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-1-S1-P243","article-title":"Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C","author":"Erbe","year":"2013"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.507.507","article-title":"Specific KIR and HLA genotypes affect outcomes of single-agent anti-CD20 immunotherapy of follicular lymphoma","volume-title":"ASH Annual Meeting (Abstract): Blood","author":"Grzywacz","year":"2013"},{"key":"B24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1146\/annurev.immunol.20.100301.064812","article-title":"Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination","volume":"20","author":"Natarajan","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.4049\/jimmunol.158.11.5237","article-title":"Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor","volume":"158","author":"Gumperz","year":"1997","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.4049\/jimmunol.1303142","article-title":"Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity","volume":"192","author":"O\u2019Connor","year":"2014","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.4049\/jimmunol.181.9.6293","article-title":"Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1","volume":"181","author":"Sanjanwala","year":"2008","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4049\/jimmunol.178.1.33","article-title":"Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B","volume":"178","author":"Thananchai","year":"2007","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1084\/jem.20152023","article-title":"Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition","volume":"213","author":"Saunders","year":"2016","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1399-0039.2008.01184.x","article-title":"A novel real-time PCR method for KIR genotyping","volume":"73","author":"Alves","year":"2009","journal-title":"Tissue Antigens"},{"key":"B31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1399-0039.2007.00923.x","article-title":"Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments","volume":"70","author":"Vilches","year":"2007","journal-title":"Tissue Antigens"},{"key":"B32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0889-8588(05)70243-4","article-title":"Antibody-directed, effector cell-mediated tumor destruction","volume":"15","author":"Sondel","year":"2001","journal-title":"Hematol Oncol Clin North Am"},{"key":"B33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nri1306","article-title":"Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future","volume":"4","author":"Vivier","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.4049\/jimmunol.181.5.3268","article-title":"Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors","volume":"181","author":"Patterson","year":"2008","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/1078-0432.CCR-16-1874","article-title":"FCGR polymorphisms influence response to IL2 in metastatic renal cell carcinoma","volume":"23","author":"Erbe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00262-016-1904-8","article-title":"Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2","volume":"65","author":"Wang","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin\u2019s lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1080\/10428190903128660","article-title":"Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma","volume":"50","author":"Weng","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1078-0432.CCR-15-1848","article-title":"Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma","volume":"22","author":"Kenkre","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1200\/JCO.2005.04.6011","article-title":"FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor","volume":"24","author":"Cheung","year":"2006","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.10548","article-title":"Correlation of killer-cell Ig like receptor (KIR) haplotypes and Fc\u03b3-receptor polymorphisms with survival of high-risk relapsed\/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18\/CHO","author":"Lode","year":"2016"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.4049\/jimmunol.1400288","article-title":"KIR\/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity","volume":"192","author":"Terszowski","year":"2014","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ng2035","article-title":"Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1","volume":"39","author":"Martin","year":"2007","journal-title":"Nat Genet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.180.4.1235","article-title":"NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80","volume":"180","author":"Cella","year":"1994","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.181.3.1133","article-title":"The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor","volume":"181","author":"Gumperz","year":"1995","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"781","DOI":"10.4049\/jimmunol.1402542","article-title":"The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope","volume":"194","author":"Saunders","year":"2015","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nature10517","article-title":"Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B","volume":"479","author":"Vivian","year":"2011","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/eji.1830260845","article-title":"Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones","volume":"26","author":"Luque","year":"1996","journal-title":"Eur J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1101\/gr.085738.108","article-title":"Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes","volume":"19","author":"Norman","year":"2009","journal-title":"Genome Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/eji.1830270231","article-title":"Binding of a soluble p70 killer cell inhibitory receptor to HLA-B*5101: requirement for all three p70 immunoglobulin domains","volume":"27","author":"Rojo","year":"1997","journal-title":"Eur J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood-2008-01-132902","article-title":"The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations","volume":"112","author":"Foley","year":"2008","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.4049\/jimmunol.175.8.5222","article-title":"KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand","volume":"175","author":"Carr","year":"2005","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20051884","article-title":"Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function","volume":"203","author":"Yawata","year":"2006","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1034\/j.1600-065X.2002.19012.x","article-title":"Natural selection and the diversification of vertebrate immune effectors","volume":"190","author":"Hughes","year":"2002","journal-title":"Immunol Rev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1600-065X.1997.tb00951.x","article-title":"Polymorphism and domain variability of human killer cell inhibitory receptors","volume":"155","author":"Selvakumar","year":"1997","journal-title":"Immunol Rev"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.4049\/jimmunol.168.5.2307","article-title":"Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype","volume":"168","author":"Shilling","year":"2002","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"D423","DOI":"10.1093\/nar\/gku1161","article-title":"The IPD and IMGT\/HLA database: allele variant databases","volume":"43","author":"Robinson","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6727","DOI":"10.4049\/jimmunol.0900212","article-title":"Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells","volume":"182","author":"Morvan","year":"2009","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/1471-2334-13-405","article-title":"KIR3DS1\/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors","volume":"13","author":"Jiang","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng934","article-title":"Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS","volume":"31","author":"Martin","year":"2002","journal-title":"Nat Genet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.4049\/jimmunol.1500243","article-title":"KIR3DS1-specific D0 domain polymorphisms disrupt KIR3DL1 surface expression and HLA binding","volume":"195","author":"Mulrooney","year":"2015","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:29:08Z","timestamp":1692836948000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,12]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2017.00675"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00675","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,12]]},"article-number":"675"}}